PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy

• Published in: Annals of surgical oncology 2016-11, Vol.23 (12), p.4093-4100
• Main Authors: Kanzaki, Ryu, Naito, Hisamichi, Kise, Kazuyoshi, Takara, Kazuhiro, Eino, Daisuke, Minami, Masato, Shintani, Yasushi, Funaki, Soichiro, Kawamura, Tomohiro, Kimura, Toru, Okumura, Meinoshin, Takakura, Nobuyuki
• Format: Article
• Language: English
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor - metabolism; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - therapy; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Proliferation - genetics; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Disease-Free Survival; DNA-Binding Proteins - genetics; DNA-Binding Proteins - metabolism; Female; Gene Knockdown Techniques; Humans; Ki-67 Antigen - metabolism; Lung Neoplasms - metabolism; Lung Neoplasms - therapy; Male; Medicine; Medicine & Public Health; Middle Aged; Neoadjuvant Therapy; Oncology; Prognosis; Proportional Hazards Models; Retrospective Studies; Surgery; Surgical Oncology; Survival Rate; Thoracic Oncology
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-016-5392-z

Background PSF1 (Partner of SLD Five 1) is an evolutionarily conserved DNA replication factor that is part of the GINS (Go, Ichi, Nii, and San) complex . The objective of this study was to evaluate the relationship between PSF1 expression and prognosis in patients with non-small cell lung cancer (NSCLC) treated with surgery following preoperative chemotherapy or chemoradiotherapy. Methods Sixty-nine patients with NSCLC treated with surgery following preoperative chemotherapy or chemoradiotherapy who did not achieve pathologic complete response were enrolled. The status of PSF1 expression was evaluated by immunohistochemistry, and the relationship between expression of PSF1 and Ki-67 was determined, as well as correlations between PSF1 expression and prognosis. Results We found that 27 of 69 patients’ tumors (39 %) were positive for PSF1 expression. The Ki-67 index was significantly higher in the PSF1-positive versus the PSF1-negative group ( p  = 0.0026). Five-year, disease-free survival of the PSF1-positive group was significantly worse (17.7 vs. 44.3 %, p  = 0.0088), and the 5-year overall survival also was worse (16.6 vs. 47.2 %, p  = 0.0059). Moreover, PSF1 expression was found to be a significant independent prognostic factor for shorter survival by Cox multivariate analysis (hazard ratio 2.43, 95 % confidence interval 1.27–4.60, p  = 0.0076). Conclusions PSF1 is a useful prognostic biomarker to stratify NSCLC patients treated with surgery following preoperative chemotherapy or chemoradiotherapy.